Management of Fungal Infection with Initial Fluconazole Response Followed by Symptom Recurrence

Critical First Steps: Identify the Specific Fungal Pathogen

The Infectious Diseases Society of America (IDSA) recommends obtaining fungal culture and susceptibility testing to identify the organism and rule out fluconazole-resistant species like Candida glabrata or Candida krusei 4
For dermatophyte infections, the IDSA explicitly states that single-dose fluconazole is inappropriate and ineffective, and is only recommended for vulvovaginal candidiasis 5
For candidemia, removing all intravascular catheters if possible is crucial, as catheter retention is a major cause of treatment failure 6

The American College of Physicians recommends increasing the fluconazole dose to 800-1200 mg daily if the original dose was lower, as this is the primary recommendation for treatment failure in coccidioidomycosis and other serious fungal infections 1, 2, 3
This applies particularly to coccidioidal meningitis and serious Candida infections 7
Clinical improvement should be evident within 7-14 days of appropriate therapy 5, 4

The IDSA recommends switching to itraconazole 200 mg 2-4 times daily if dose escalation fails or is not tolerated, though this requires closer monitoring for adequate absorption and has more drug-drug interactions than fluconazole 1, 2, 3
Switching to voriconazole 200 mg twice daily is recommended for selected cases, particularly for fluconazole-resistant Candida krusei or voriconazole-susceptible Candida glabrata 6, 4

The causative Candida species determines optimal management, with C. albicans allowing continuation of fluconazole if clinically stable, and C. glabrata requiring echinocandin or amphotericin B 6
C. krusei is inherently fluconazole-resistant and requires echinocandin, liposomal amphotericin B, or voriconazole 6

The IDSA recommends using amphotericin B for very severe and/or rapidly progressing infections, until the patient stabilizes, followed by fluconazole 1, 2
Intrathecal amphotericin B is an option for coccidioidal meningitis failing oral azoles 1, 2, 3

For coccidioidal meningitis, azole treatment must continue for life, as azoles suppress rather than cure the infection 1, 2, 3, 7
For candidemia without metastatic complications, treatment should continue for 14 days after the first negative blood culture and resolution of symptoms 6

The American Heart Association recommends avoiding oral fluconazole entirely if the patient is taking clopidogrel, due to moderate-to-strong CYP2C19 inhibition that reduces antiplatelet effect and increases cardiovascular risk 4